Rebamipide ameliorates indomethacin-induced small intestinal injury in rats via the inhibition of matrix metalloproteinases activity

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 12, 2012, Pages 1816-1824

  Yamada, Shinya ^a   Naito, Yuji ^a   Takagi, Tomohisa ^a   Mizushima, Katsura ^a   Horie, Ryusuke ^a   Fukumoto, Kohei ^a   Inoue, Ken ^a   Harusato, Akihito ^a   Uchiyama, Kazuhiko ^a   Handa, Osamu ^a   Yagi, Nobuaki ^a   Ichikawa, Hiroshi ^b   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

Author keywords

Indomethacin; Matrix metalloproteinase; Microarray analysis; Rebamipide; Small intestinal injury

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; CHEMOKINE; COLLAGENASE 3; INDOMETACIN; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; METALLOTHIONEIN; METALLOTHIONEIN 1A; REBAMIPIDE; STROMELYSIN; STROMELYSIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; INTESTINE INJURY; INTESTINE MUCOSA; MALE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; UPREGULATION;

ALANINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOKINES; DOWN-REGULATION; INDOMETHACIN; INJECTIONS, SUBCUTANEOUS; INTESTINAL MUCOSA; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; METALLOTHIONEIN; QUINOLONES; RATS; RATS, WISTAR; UP-REGULATION;

EID: 84869805100     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07275.x     Document Type: Article

References (48)

1. Ishihara M, Ohmiya N, Goto H. [Trend view on nonsteroidal anti-inflammatory drug-induced small bowel injury]. Nihon Shokakibyo Gakkai Zasshi 2010; 107: 1905-1909.
2. Morris AJ, Madhok R, Sturrock RD, Capell HA, MacKenzie JF. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 520.
3. Fujimori S, Seo T, Gudis K etal. Diagnosis and treatment of obscure gastrointestinal bleeding using combined capsule endoscopy and double balloon endoscopy: 1-year follow-up study. Endoscopy 2007; 39: 1053-1058.
4. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847.
5. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1992; 327: 749-754.
6. Wallace JL, Syer S, Denou E etal. Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis. Gastroenterology 2011; 141: 1314-1322.
7. Kuroda M, Yoshida N, Ichikawa H etal. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int. J. Mol. Med. 2006; 17: 89-93.
8. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev. Gastroenterol. Hepatol. 2010; 4: 261-270.
9. Suetsugu H, Ishihara S, Moriyama N etal. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J. Lab. Clin. Med. 2000; 136: 50-57.
10. Sun WH, Tsuji S, Tsujii M etal. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J. Pharmacol. Exp. Ther. 2000; 295: 447-452.
11. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig. Dis. Sci. 1993; 38: 1441-1449.
12. Shimoyama T, Fukuda S, Liu Q, Fukuda Y, Nakaji S, Sugawara K. Characteristics of attenuating effects of rebamipide, an anti-ulcer agent, on oxidative burst of human neutrophils. J. Pharmacol. Sci. 2003; 91: 153-157.
13. Yoshikawa T, Naito Y, Nakamura S etal. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneimittelforschung 1993; 43: 1327-1330.
14. Naito Y, Yoshikawa T, Iinuma S etal. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig. Dis. Sci. 1998; 43: 83S-89.
15. Naito Y, Kuroda M, Mizushima K etal. Transcriptome analysis for cytoprotective actions of rebamipide against indomethacin-induced gastric mucosal injury in rats. J. Clin. Biochem. Nutr. 2007; 41: 202-210.
16. Fujimori S, Takahashi Y, Gudis K etal. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 2011; 46: 57-64.
17. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J. Gastroenterol. Hepatol. 2001; 16: 1112-1119.
18. Yamada A, Uegaki A, Nakamura T, Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm. Res. 2000; 49: 144-146.
19. Yamada S, Naito Y, Takagi T etal. Reduced small-intestinal injury induced by indomethacin in interleukin-17A-deficient mice. J. Gastroenterol. Hepatol. 2011; 26: 398-404.
20. Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am. J. Physiol. 1986; 251: G567-574.
21. Radomski A, Sawicki G, Olson DM, Radomski MW. The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br. J. Pharmacol. 1998; 125: 1455-1462.
22. Medina C, Videla S, Radomski A etal. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2003; 284: G116-122.
23. Fernandez-Patron C, Martinez-Cuesta MA, Salas E etal. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb. Haemost. 1999; 82: 1730-1735.
24. Takagi T, Naito Y, Okada H etal. Identification of dihalogenated proteins in rat intestinal mucosa injured by indomethacin. J. Clin. Biochem. Nutr. 2011; 48: 178-182.
25. Stadnyk AW, Dollard C, Issekutz TB, Issekutz AC. Neutrophil migration into indomethacin induced rat small intestinal injury is CD11a/CD18 and CD11b/CD18 co-dependent. Gut 2002; 50: 629-635.
26. Fukumoto K, Naito Y, Takagi T etal. Role of tumor necrosis factor-alpha in the pathogenesis of indomethacin-induced small intestinal injury in mice. Int. J. Mol. Med. 2011; 27: 353-359.
27. Yoshida N, Ishikawa T, Ichiishi E etal. The effect of rebamipide on Helicobacter pylori extract-mediated changes of gene expression in gastric epithelial cells. Aliment. Pharmacol. Ther. 2003; 18 (Suppl. 1): 63-75.
28. Higuchi K, Umegaki E, Watanabe T etal. Present status and strategy of NSAIDs-induced small bowel injury. J. Gastroenterol. 2009; 44: 879-888.
29. Satoh H, Shiotani S, Otsuka N, Hatao K, Nishimura S. Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats. Gut 2009; 58: 1590-1596.
30. Hatazawa R, Ohno R, Tanigami M, Tanaka A, Takeuchi K. Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats. J. Pharmacol. Exp. Ther. 2006; 318: 691-699.
31. Evans SM, Whittle BJ. Role of bacteria and inducible nitric oxide synthase activity in the systemic inflammatory microvascular response provoked by indomethacin in the rat. Eur. J. Pharmacol. 2003; 461: 63-71.
32. Fuji Y, Matsura T, Kai M, Kawasaki H, Yamada K. Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. Jpn J. Pharmacol. 2000; 84: 63-70.
33. Nagano Y, Matsui H, Muramatsu M etal. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig. Dis. Sci. 2005; 50 (Suppl. 1): S76-83.
34. Laukens D, Waeytens A, De Bleser P, Cuvelier C, De Vos M. Human metallothionein expression under normal and pathological conditions: mechanisms of gene regulation based on in silico promoter analysis. Crit. Rev. Eukaryot. Gene Expr. 2009; 19: 301-317.
35. Waeytens A, De Vos M, Laukens D. Evidence for a potential role of metallothioneins in inflammatory bowel diseases. Mediators Inflamm. 2009; 2009: Article ID 729172.
36. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J. Pathol. 2003; 201: 28-36.
37. Youn J, Hwang SH, Ryoo ZY etal. Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and down-regulation of proinflammatory mediators. Clin. Exp. Immunol. 2002; 129: 232-239.
38. Penkowa M, Hidalgo J. Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-alpha and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp. Neurol. 2001; 170: 1-14.
39. Tran CD, Ball JM, Sundar S, Coyle P, Howarth GS. The role of zinc and metallothionein in the dextran sulfate sodium-induced colitis mouse model. Dig. Dis. Sci. 2007; 52: 2113-2121.
40. Sivalingam N, Pichandi S, Chapla A, Dinakaran A, Jacob M. Zinc protects against indomethacin-induced damage in the rat small intestine. Eur. J. Pharmacol. 2011; 654: 106-116.
41. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 2004; 4: 617-629.
42. Kakimoto K, Takai S, Murano M etal. Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J. Pharmacol. Exp. Ther. 2010; 332: 684-689.
43. Matsumoto H, Koga H, Iida M, Tarumi K, Fujita M, Haruma K. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats. Scand. J. Gastroenterol. 2006; 41: 1320-1329.
44. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. 2003; 253: 269-285.
45. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007; 26: 587-596.
46. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J. Pharmacol. Exp. Ther. 2006; 318: 933-938.
47. Warner RL, Beltran L, Younkin EM etal. Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am. J. Respir. Cell Mol. Biol. 2001; 24: 537-544.
48. Warner RL, Lewis CS, Beltran L, Younkin EM, Varani J, Johnson KJ. The role of metalloelastase in immune complex-induced acute lung injury. Am. J. Pathol. 2001; 158: 2139-2144.